A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer
Prostate Cancer
DRUG: BMS-641988 (AR#2)
To assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer, throughout the study
To evaluate the pharmacokinetics of BMS-641988 and the metabolites BMS-501949 and BMS-570511, at cycle 1 day 1, day 15 and day 29|To identify the dose(s) of BMS-641988 for Phase II, at the end of study|To assess any preliminary evidence of anti-tumor activity by PSA decline, tumor shrinkage, radionuclide bone scans, throughout the study|To assess the effects of BMS-641988 on pharmacodynamic markers (LH, total and free testosterone, 5(alpha)-DHT, estradiol, prolactin, FSH, and SHBG), throughout the study
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer